UK Could Face Medicine Shortages Within Weeks as Iran War Disrupts Supply Chains
Britain is just "a few weeks away" from experiencing significant medicine shortages ranging from basic painkillers to critical cancer treatments if the ongoing conflict involving Iran continues, according to supply chain experts. The situation threatens to disrupt the availability of health essentials while potentially driving up drug prices across the healthcare system.
Perfect Storm for Pharmaceutical Supply Chains
The conflict has created what experts describe as "the perfect storm" for pharmaceutical supply chains, disrupting the flow of crucial raw materials including oil, gas, crop fertilizers, and helium. David Weeks, director of supply chain risk management at Moody's analytics group, explained the complex situation: "We have the conflict in the Gulf that caused the Strait of Hormuz to shut down, and India is known as the pharmacy of the world. They produce a lot of the generic drugs and active pharmaceutical ingredients. With the geopolitical situation, it's harder and harder to get those out."
India produces approximately 60% of generic medicines used globally and supplies half of US pharmaceutical requirements, making disruptions to Indian exports particularly concerning for global healthcare systems.
Transportation Crisis Deepens
The transportation network for medicines faces multiple challenges:
- Air freight has been severely impacted with airports in Dubai, Doha, and Abu Dhabi initially closing and now operating limited schedules
- Shipping routes are under strain due to the near-total closure of the Strait of Hormuz
- Air cargo levels dropped 80% earlier this month and remain significantly reduced
- Before the conflict, approximately 3,700 passenger flights carrying cargo transited through the region daily
Mark Samuels, chief executive of Medicines UK, which represents manufacturers of generic drugs that make up 85% of medications used by the NHS, stated: "We're not in a crisis currently but it's still a serious situation." He warned that if the conflict continues, drug shortages could emerge within weeks.
Critical Medicines at Risk
Certain essential medicines require air transport due to their time-sensitive nature or special storage requirements:
- Expensive cancer treatments
- Infectious disease medications
- Hi-tech cell and gene therapies
- Biologics requiring cold storage
- Drugs used in clinical trials
While healthcare cargo receives priority over commercial goods, the reduced air capacity creates significant challenges. Sea transport offers an alternative for stable generic drugs, but ships must now sail around the Cape of Good Hope, adding 14 days to journey times and approximately $1 million in additional fuel costs.
Financial Pressures Mount
The conflict has already doubled air freight costs, creating financial strain on pharmaceutical companies. Samuels noted: "One in five NHS medicines comes in by air, and currently manufacturers are trying to absorb those costs. But they've got historically low margins, and the risk is that it makes some medicines lossmaking to supply to the NHS."
While suppliers have long-term pricing agreements with NHS hospitals, they maintain flexibility for drugs supplied to GP practices and pharmacies, where price increases could occur. Wouter Dewulf, a pharmaceutical logistics expert at Antwerp Management School, expects drugmakers to implement single-digit price increases if the situation worsens.
Broader Economic Impact
The ripple effects extend beyond transportation costs. Rising crude oil and natural gas prices increase costs for petrochemical products essential to pharmaceutical manufacturing:
- Methanol and ethylene needed for active pharmaceutical ingredients
- Medical supplies including syringes, vials, tubing, gowns, and goggles
Frank Van Gelder, a healthcare supply chain strategist and secretary general of Pharma.Aero, emphasized the broader implications: "So the overall ripple effect on industry and in this case the life science and pharma industry is significant. Who is going to pay for that?" He concluded that ultimately patients would bear the costs either directly or through publicly funded health systems like the NHS.
Medical distributors typically maintain six to eight weeks of stock to prevent shortages, while hospital suppliers in England must hold eight weeks' worth. During the COVID-19 pandemic, Britain experienced shortages of paracetamol and other painkillers as Indian manufacturers struggled to meet global demand, highlighting the vulnerability of current supply chains.
The UK produces approximately half of its medicines domestically, with a third coming from India and additional supplies from the EU. As the conflict continues, healthcare systems face mounting pressure to secure essential medications while managing escalating costs that could ultimately affect patient care and treatment accessibility.
